SAN DIEGO, Feb. 28, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2018 and provided an update on its corporate activities and product pipeline. "Our global Phase 3 ReSTORE trial of rezafungin, for the treatment of patients with candidemia and invasive candidiasis, is enrolling patients and progressing in line with expectations. We also continue…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019. "The TCT meeting is an important venue for Cidara to share data that demonstrate the potential advantages…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary. "We are extremely pleased to welcome Jamie and Jessica to our executive management team. They both have deep, highly relevant experience and distinguished leadership track records in the biotech industry, all of which will be extremely valuable to…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting will be held December 1-4 in San Diego. The rezafungin ASH abstract (2071), titled "Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis…

Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area. "We are once…

SAN DIEGO, Nov. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate activities and product pipeline. "We made considerable progress during the third quarter of 2018 with the initiation of our Phase 3 ReSTORE trial of rezafungin, for the treatment of invasive candida infections, and the granting by the…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance (AMR) Congress taking place October 25-26, 2018 in Washington, DC. The presentation, titled "Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against multi-drug resistant bacterial infections," is scheduled for 11:10 a.m. Eastern Time on…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. A total of three rezafungin…

STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara's novel once-weekly antifungal agent SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company's Phase 2 STRIVE trial of rezafungin at IDWeek…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. "Given the…